Bempedoic acid and/or its fixed dose combination with ezetimibe
Pre-clinicalWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hypercholesterolemia
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Trial Timeline
Sep 1, 2023 → Apr 1, 2026
NCT ID
NCT05798390About Bempedoic acid and/or its fixed dose combination with ezetimibe
Bempedoic acid and/or its fixed dose combination with ezetimibe is a pre-clinical stage product being developed by Daiichi Sankyo for Primary Hypercholesterolemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05798390. Target conditions include Primary Hypercholesterolemia, Mixed Dyslipidemia.
What happened to similar drugs?
20 of 20 similar drugs in Primary Hypercholesterolemia were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
3
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05798390 | Pre-clinical | Withdrawn |
Competing Products
20 competing products in Primary Hypercholesterolemia